Pharmacokinetics and tolerability of cabotegravir and rilpivirine long-acting intramuscular injections to the <i>vastus lateralis</i> (lateral thigh) muscles of healthy adult participants.

ABSTRACT: Cabotegravir + rilpivirine administered via intramuscular gluteal injections is the first complete long-acting (LA) regimen approved for maintaining HIV-1 virologic suppression. The vastus lateralis (lateral) thigh muscle could be a potential alternative site of administration in circumstances such as injection site fatigue, intolerability, or contraindication for gluteal administration. Cabotegravir and rilpivirine pharmacokinetics and participant tolerability were evaluated following single intramuscular injections to the lateral thigh. Healthy adult participants received 4 weeks of daily oral cabotegravir (30 mg) and rilpivirine (25 mg), followed by a 10- to 14-day washout and single 3 mL intramuscular injections of cabotegravir LA 600 mg and rilpivirine LA 900 mg to the lateral

SUBMITTER: Han K 

PROVIDER: S-EPMC10777827 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature